The Business Research Company’s report on the All-Terrain Vehicle (ATV) and Utility Task Vehicle (UTV) Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market’s growth in recent years?
The increasing number of clinical trials is expected to propel the growth of the advanced therapy medicinal products CDMO market going forward. Clinical trials are research studies conducted in humans to evaluate the safety and efficacy of medical interventions such as drugs, treatments, devices, or preventive measures. Clinical trial numbers are rising to meet the increasing demand for innovative treatments and to address a growing global disease burden. With the use of advanced therapy medicinal products, the demand for CDMO manufacturing services rises, leveraging specialized expertise and infrastructure. Clinical trial data aids in optimizing manufacturing, ensuring scalability, and quality maintenance to meet larger clinical and commercial needs. For instance, in November 2023, according to the Association of the British Pharmaceutical Industry, a UK-based trade association, the overall number of industry clinical trials initiated in the UK per year increased marginally by 4.3%, from 394 in 2021 to 411 in 2022. Therefore, the increasing number of clinical trials is driving the growth of the advanced therapy medicinal products CDMO market.
Access Your Free Sample of the Global All-Terrain Vehicle (ATV) and Utility Task Vehicle (UTV) Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15719&type=smp
How does the future projection of the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market size compare to its historical growth?
The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market size has grown rapidly in recent years. It will grow from $5.31 billion in 2024 to $6.22 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to the increasing number of ATMP clinical trials, rising awareness and belief among researchers regarding the benefits of advanced therapy, the presence of several ATMP CDMOs, increasing efforts to develop novel therapies for various diseases, and supportive government initiatives.
The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market size is expected to see rapid growth in the next few years. It will grow to $11.53 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to the high investment of CDMOs, a growing number of emerging players in the cell and gene therapy (CGT) sector, increasing grants and investments for the development of cell and gene therapies, increasing pharmaceutical R&D spending, increasing number of clinical trials for ATMPs. Major trends in the forecast period include advancements in AAV biomanufacturing facilities, expansion of cell and gene therapy manufacturing, technological advancements in cell and gene therapy, increasing need for access to advanced platforms and technologies, and incorporating advanced technologies such as CRISPR and next-generation sequencing for heightened accuracy.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=15719&type=smp
Which key players are shaping the future of the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market?
Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market are Thermo Fisher Scientific Inc., Merck KGaA, Resonac Corporation, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions
What trends will propel the growth and evolution of the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market?
Major companies operating in the advanced therapy medicinal products CDMO market are developing advanced cell therapy manufacturing services to overcome critical issues in cell therapy manufacturing and speed the development activities of their partners. Cell therapy manufacturing services are contract development and manufacturing organization services that offer services which vary from early preclinical development to late-stage clinical trials and commercialization. For instance, in January 2024, Pluristem Therapeutics Inc., an Israel-based biotech company that transforms cells into solutions, launched PluriCDMO, a new business division offering cell therapy manufacturing. It utilizes a patented bioreactor system that allows for 3D cell multiplication, facilitating the production of a variety of cell types such as stem cells, induced pluripotent stem cells, exosomes, and immune therapies. PluriCDMO desires to provide high-quality, vital medicines to patients while maintaining unique batch-to-batch consistency in a scalable and cost-effective manner in good manufacturing practice settings.
Which regions are expected to become dominant players in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market?
North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
What are the emerging key segments in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market, and how are they evolving?
The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology
Subsegments:
1) By Gene Therapy: Viral Vectors, Non-Viral Vectors, Dna Or Rna-Based Products
2) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy
3) By Tissue Engineered: Skin Substitutes, Cartilage And Bone Tissue, Vascular Grafts And Organs
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15719
How is the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market defined, and what are its core characteristics?
An advanced therapy medicinal product contract development and manufacturing organization (CDMO) is a specialized service provider that assists in the development and manufacturing of advanced therapy medicinal products. The objective of an advanced therapy medicinal product CDMO is to provide the expertise, infrastructure, and resources required for advanced therapy medicinal product development and manufacturing.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
